Atomo Investor Webinar Presentation
Released
Released
Announcement PDF
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
ASX Announcement 23rd
January 2026
Atomo Q2 FY26 Quarterly Investor Webinar Presentation
SYDNEY Australia, 23rd January 2026 – Atomo Diagnostics Limited (ASX: AT1) (Atomo or the
Company) will release its Q2 FY26 Results on Wednesday, 28th January 2026.
A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly
will be held on Wednesday, 28th January 2026 at 2:00 pm (AEDT).
To access the webinar please pre-register by clicking this link.
We encourage you to utilise our Investor Hub for any enquiries. This platform offers an opportunity to
submit questions prior to the webinar and share comments. To access Atomo’s Investor Hub please
scan the QR code or visit
https://investors.atomodiagnostics.com/auth/signup
~ ENDS ~
For more information, please contact:
John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279
Investor Queries
investorqueries@atomodiagnostics.com
This announcement was authorised by the Managing Director & CEO on behalf of the Board.
About Atomo
Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid
diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify
testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-
home testing applications. The Company has successfully commercialised a number of products across
international markets and has supply agreements in place for testing applications targeting infectious
diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at
www.atomodiagnostics.com
Share your feedback
Discover